Inventor · disambiguated record
Matthieu Chodorge
Also filed as: CHODORGE MATTHIEU
8 granted patents·3 pending applications·515 citations·filing 2005–2022
86Inventor score
Top patents by PatentIndex Score
11 records- 0195US9493565B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2014·Granted Nov 15, 2016·50 cites·8 claims
- 0295US8779108B2Targeted binding agents against B7-H1QUEVA CHRISTOPHE·Filed 2010·Granted Jul 15, 2014·452 cites·31 claims
- 0390US10400039B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2016·Granted Sep 3, 2019·8 cites·8 claims
- 0480US2023235062A1Targeted binding agents against b7-h1MEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 0575US11078284B2Antibodies specific for LOX1 and use in treatment of cardiovascular disordersMEDIMMUNE LTD·Filed 2018·Granted Aug 3, 2021·1 cites·19 claims
- 0675US10077319B2Anti-PCSK9-GLP-1 fusions and methods for useMEDIMMUNE LLC·Filed 2015·Granted Sep 18, 2018·3 cites·20 claims
- 0767US11518809B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2019·Granted Dec 6, 2022·0 cites·11 claims
- 0867US10117889B2Antibodies specific for LOX1 and use in treatment of cardiovascular disordersMEDIMMUNE LTD·Filed 2015·Granted Nov 6, 2018·1 cites·20 claims
- 0964US2021347900A1Antibodies specific for lox1 and use in treatment of cardiovascular disordersMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 1050US7983849B2Method of determining the mutational load of a gene library obtained by random mutagenesis of a particular gene and means for implementing samePROTEUS SA·Filed 2005·Granted Jul 19, 2011·0 cites·29 claims
- 1141US2019092877A1Anti-pcsk9-glp-1 fusions and methods for useMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →